{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:37:44Z","timestamp":1791214664345,"version":"4.1.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2012,7,24]]},"abstract":"<jats:sec>\n            <jats:title>Background\u2014<\/jats:title>\n            <jats:p>Epigenetic programming, dynamically regulated by histone acetylation, is a key mechanism regulating cell proliferation and survival. Little is known about the contribution of histone deacetylase (HDAC) activity to the development of pulmonary arterial hypertension, a condition characterized by profound structural remodeling of pulmonary arteries and arterioles.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results\u2014<\/jats:title>\n            <jats:p>HDAC1 and HDAC5 protein levels were elevated in lungs from human idiopathic pulmonary arterial hypertension and in lungs and right ventricles from rats exposed to hypoxia. Immunohistochemistry localized increased expression to remodeled vessels in the lung. Both valproic acid, a class I HDAC inhibitor, and suberoylanilide hydroxamic acid (vorinostat), an inhibitor of class I, II, and IV HDACs, mitigated the development of and reduced established hypoxia-induced pulmonary hypertension in the rat. Both valproic acid and suberoylanilide hydroxamic acid inhibited the imprinted highly proliferative phenotype of fibroblasts and R-cells from pulmonary hypertensive bovine vessels and platelet-derived growth factor\u2013stimulated growth of human vascular smooth muscle cells in culture. Exposure to valproic acid and suberoylanilide hydroxamic acid was associated with increased levels of p21 and FOXO3 and reduced expression of survivin. The significantly higher levels of expression of cKIT, monocyte chemoattractant protein-1, interleukin-6, stromal-derived factor-1, platelet-derived growth factor-b, and S100A4 in R-cells were downregulated by valproic acid and suberoylanilide hydroxamic acid treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions\u2014<\/jats:title>\n            <jats:p>Increased HDAC activity contributes to the vascular pathology of pulmonary hypertension. The effectiveness of HDAC inhibitors, valproic acid, and suberoylanilide hydroxamic acid, in models of pulmonary arterial hypertension supports a therapeutic strategy based on HDAC inhibition in pulmonary arterial hypertension.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circulationaha.112.103176","type":"journal-article","created":{"date-parts":[[2012,6,19]],"date-time":"2012-06-19T03:57:24Z","timestamp":1340078244000},"page":"455-467","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":248,"title":["Histone Deacetylation Inhibition in Pulmonary Hypertension"],"prefix":"10.1161","volume":"126","author":[{"given":"Lan","family":"Zhao","sequence":"first","affiliation":[{"name":"From the Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK (L.Z., C.-N.C., N.H., E.O., E.C., J.W., M.R.W.), and Department of Pediatrics, Division of Critical Care Medicine (D.W., M.L., K.R.S.), and Department of Medicine, Division of Cardiology (T.A.M.), University of Colorado Denver, Denver."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Nien","family":"Chen","sequence":"additional","affiliation":[{"name":"From the Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK (L.Z., C.-N.C., N.H., E.O., E.C., J.W., M.R.W.), and Department of Pediatrics, Division of Critical Care Medicine (D.W., M.L., K.R.S.), and Department of Medicine, Division of Cardiology (T.A.M.), University of Colorado Denver, Denver."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Hajji","sequence":"additional","affiliation":[{"name":"From the Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK (L.Z., C.-N.C., N.H., E.O., E.C., J.W., M.R.W.), and Department of Pediatrics, Division of Critical Care Medicine (D.W., M.L., K.R.S.), and Department of Medicine, Division of Cardiology (T.A.M.), University of Colorado Denver, Denver."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Oliver","sequence":"additional","affiliation":[{"name":"From the Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK (L.Z., C.-N.C., N.H., E.O., E.C., J.W., M.R.W.), and Department of Pediatrics, Division of Critical Care Medicine (D.W., M.L., K.R.S.), and Department of Medicine, Division of Cardiology (T.A.M.), University of Colorado Denver, Denver."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cotroneo","sequence":"additional","affiliation":[{"name":"From the Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK (L.Z., C.-N.C., N.H., E.O., E.C., J.W., M.R.W.), and Department of Pediatrics, Division of Critical Care Medicine (D.W., M.L., K.R.S.), and Department of Medicine, Division of Cardiology (T.A.M.), University of Colorado Denver, Denver."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wharton","sequence":"additional","affiliation":[{"name":"From the Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK (L.Z., C.-N.C., N.H., E.O., E.C., J.W., M.R.W.), and Department of Pediatrics, Division of Critical Care Medicine (D.W., M.L., K.R.S.), and Department of Medicine, Division of Cardiology (T.A.M.), University of Colorado Denver, Denver."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daren","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK (L.Z., C.-N.C., N.H., E.O., E.C., J.W., M.R.W.), and Department of Pediatrics, Division of Critical Care Medicine (D.W., M.L., K.R.S.), and Department of Medicine, Division of Cardiology (T.A.M.), University of Colorado Denver, Denver."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[{"name":"From the Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK (L.Z., C.-N.C., N.H., E.O., E.C., J.W., M.R.W.), and Department of Pediatrics, Division of Critical Care Medicine (D.W., M.L., K.R.S.), and Department of Medicine, Division of Cardiology (T.A.M.), University of Colorado Denver, Denver."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"McKinsey","sequence":"additional","affiliation":[{"name":"From the Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK (L.Z., C.-N.C., N.H., E.O., E.C., J.W., M.R.W.), and Department of Pediatrics, Division of Critical Care Medicine (D.W., M.L., K.R.S.), and Department of Medicine, Division of Cardiology (T.A.M.), University of Colorado Denver, Denver."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt R.","family":"Stenmark","sequence":"additional","affiliation":[{"name":"From the Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK (L.Z., C.-N.C., N.H., E.O., E.C., J.W., M.R.W.), and Department of Pediatrics, Division of Critical Care Medicine (D.W., M.L., K.R.S.), and Department of Medicine, Division of Cardiology (T.A.M.), University of Colorado Denver, Denver."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Wilkins","sequence":"additional","affiliation":[{"name":"From the Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK (L.Z., C.-N.C., N.H., E.O., E.C., J.W., M.R.W.), and Department of Pediatrics, Division of Critical Care Medicine (D.W., M.L., K.R.S.), and Department of Medicine, Division of Cardiology (T.A.M.), University of Colorado Denver, Denver."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.006"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.009"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.108.847707"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/embo-reports\/kvf053"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00644-X"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.06.017"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.76.052705.162114"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.07.002"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2485"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1779"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100479"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.111.258426"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201007-1106OC"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.110.972745"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc2901.093117"},{"key":"e_1_3_3_17_2","first-page":"335","article-title":"Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study","volume":"28","author":"Rodriguez-Menendez V","year":"2008","unstructured":"Rodriguez-Menendez V, Gilardini A, Bossi M, Canta A, Oggioni N, Carozzi V, Tremolizzo L, Cavaletti G . Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study. Anticancer Res. 2008; 28: 335\u2013342.","journal-title":"Anticancer Res"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20104"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0437870100"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.90611.2008"},{"key":"e_1_3_3_21_2","first-page":"633","article-title":"The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells","volume":"31","author":"Fedier A","year":"2007","unstructured":"Fedier A, Dedes KJ, Imesch P, Von Bueren AO, Fink D . The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol. 2007; 31: 633\u2013641.","journal-title":"Int J Oncol"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-012-9499-7"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283383564"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvn014"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2010.510514"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604199"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/21.11.2672"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.4161\/cc.10.3.14712"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2001.tb02153.x"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31815f2c2a"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000111106"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-007-7079-x"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101287200"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.24.6969"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.11.003"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210204"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.0800109"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210610"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505585102"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607518103"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01500-09"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.180316197"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar3071"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1160"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23203"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-09-0580"},{"key":"e_1_3_3_48_2","first-page":"8492","article-title":"The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells","volume":"61","author":"Munster PN","year":"2001","unstructured":"Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM . The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001; 61: 8492\u20138497.","journal-title":"Cancer Res"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm200620f"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.112.103176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:46:51Z","timestamp":1715582811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.112.103176"}},"subtitle":["Therapeutic Potential of Valproic Acid and Suberoylanilide Hydroxamic Acid"],"short-title":[],"issued":{"date-parts":[[2012,7,24]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7,24]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.112.103176"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.112.103176","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,24]]},"assertion":[{"value":"2011-10-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-06-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}